Literature DB >> 15024530

The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits.

Kyung Koo Kang1, Seul Min Choi, Gook Jun Ahn, Jong Won Kwon, Won Bae Kim.   

Abstract

A previous study showed that DA-8159, a potent type 5 phosphodiesterase inhibitor, enhanced the relaxation of the smooth muscles in the normal rabbit corpus cavernosum. In this study, we investigated the in vitro effects of DA-8159 on cavernosal smooth muscle relaxation and the in vivo erectogenic potential in diabetic rabbits, since erectile dysfunction is a well-known sequela of diabetes mellitus. Diabetes mellitus was induced in male New Zealand White rabbits with alloxan monohydrate. Cavernosal strips from age-matched control and 8-week diabetic animals were mounted in organ baths. The relaxation responses to sodium nitroprusside (10(-9)--10(-5) M), a nitric oxide donor, were assessed in the presence or absence of DA-8159 (10(-9)--10(-6) M). For the penile erection test, DA-8159 was given orally (1-10 mg/kg) to diabetic rabbits and the length of the uncovered penile shaft was measured in a time-course manner in the presence or absence of intravenous sodium nitroprusside. The sodium nitroprusside-stimulated relaxations were significantly impaired in the corpus cavernosum from the diabetic group (IC(50)=1.07 x 10(-6) M following 8 weeks of diabetes mellitus; compared with 0.48 x 10(-6) M for age-matched controls). DA-8159 significantly and dose-dependently enhanced the sodium nitroprusside-stimulated relaxation in the diabetic groups. In addition, DA-8159 induced a dose-dependent penile erection in diabetic rabbits, which was potentiated by intravenous sodium nitroprusside. These results suggest that DA-8159 is an effective treatment for diabetic erectile dysfunction but further evaluation of the efficacy on human needs to be performed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024530     DOI: 10.1007/s00240-003-0387-1

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  27 in total

1.  Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum.

Authors:  V K Gopal; S H Francis; J D Corbin
Journal:  Eur J Biochem       Date:  2001-06

Review 2.  Cyclic GMP phosphodiesterase-5: target of sildenafil.

Authors:  J D Corbin; S H Francis
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

3.  Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro.

Authors:  J Y Jeremy; S A Ballard; A M Naylor; M A Miller; G D Angelini
Journal:  Br J Urol       Date:  1997-06

Review 4.  Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs).

Authors:  D M Juilfs; S Soderling; F Burns; J A Beavo
Journal:  Rev Physiol Biochem Pharmacol       Date:  1999       Impact factor: 5.545

Review 5.  Evaluation and treatment of erectile dysfunction in men with diabetes mellitus.

Authors:  Jayant Dey; Mark Devin Shepherd
Journal:  Mayo Clin Proc       Date:  2002-03       Impact factor: 7.616

6.  Corporal reactivity to adenosine and prostaglandin E1 in alloxan-induced diabetic rabbit corpus cavernosum, and the effect of insulin therapy.

Authors:  S Ayan; S Yildirim; C Uçar; Y Sarioglu; Y Gültekin; C Bütüner
Journal:  BJU Int       Date:  1999-01       Impact factor: 5.588

Review 7.  Cyclic nucleotide phosphodiesterases: relating structure and function.

Authors:  S H Francis; I V Turko; J D Corbin
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

8.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

Authors:  R M Wallis; J D Corbin; S H Francis; P Ellis
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

9.  FR226807: a potent and selective phosphodiesterase type 5 inhibitor.

Authors:  N Hosogai; K Hamada; M Tomita; A Nagashima; T Takahashi; T Sekizawa; T Mizutani; Y Urano; A Kuroda; K Sawada; T Ozaki; J Seki; T Goto
Journal:  Eur J Pharmacol       Date:  2001-10-05       Impact factor: 4.432

10.  Gonadal dysfunction in diabetic men with organic impotence.

Authors:  F T Murray; H U Wyss; R G Thomas; M Spevack; A G Glaros
Journal:  J Clin Endocrinol Metab       Date:  1987-07       Impact factor: 5.958

View more
  1 in total

Review 1.  Udenafil for the treatment of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.